Alterations polymorphonuclear leukocyte glycogen metabolism glucose uptake dialysis patients Human polymorphonuclear leukocytes PMNs extracorporeal circulation indicator PMN activation glycogen-degrading enzyme phosphorylase unknown dialysis therapy PMN carbohydrate metabolism PMNs healthy control subjects patients continuous ambulatory peritoneal dialysis CAPD patients regular hemodialysis therapy RDT end hemodialysis HD treatment dialyzers polysulfone polymethylmethacrylate PMMA Nifedipine NIF HD PMMA patients dose micrograms/kg body hour Glycogen activity glycogen synthetase phosphorylase active inactive forms enzymes glucose uptake stimulation chemotactic peptide FMLP PMNs HD PMMA significant increase PMN phosphorylase activity minutes start HD HD polysulfone active form glycogen-degrading enzyme PMNs HD PMMA active I-form glycogen synthetase polysulfone glycogen synthetase NIF phosphorylase activation HD PMMA PMN glycogen content glucose uptake HD polysulfone PMMA PMN glycogen content activity glycogen synthetase glucose uptake CAPD patients healthy controls data HD PMMA PMN glycogenolysis effect calcium channel blockers PMN glycogen content RDT CAPD patients healthy controls due inhibition glycogen synthesis Elimination dialyzable factor PMN glycogen synthesis glucose uptake 